Guangyu An

Dr. Guangyu An


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
CZCaicun Zhou
Caicun Zhou
GCGongyan Chen
Gongyan Chen
YHYun Chao Huang
Yun Chao Huang
JZJianying Zhou
Jianying Zhou
LLLi-Zhu Lin
Li-Zhu Lin
WSWei Shi
Wei Shi
Background: CameL phase 3 study demonstrated the superiority of camrelizumab plus chemotherapy over chemotherapy alone for progression-free survival in patients with previously untreated advanced non-squamous non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations. Here, we present the 5-year outcomes. Methods: Patients were randomized (1:1) and received 4–6 cycles of camrelizumab plus carboplatin and pemetrexed (n=205) or carboplatin and pemetrexed (n=207) every 3 weeks, followed by maintenance camrelizumab plus pemetrexed or pemetrexed only. Crossover from chemotherapy group to camrelizumab monotherapy was permitted after disease progression. Results: Median time from randomization to data cut-off was 65.2 months (range, 59.7–72.2). HR for overall survival (OS) was 0.74 (95% CI 0.58 to 0.93; one-sided p=0.0043), and was 0.62 (95% CI 0.49 to 0.79; one-sided p<0.0001) after adjustment for crossover. Five-year OS rates were 31.2% (95% CI 24.7% to 37.9%) with camrelizumab plus chemotherapy versus 19.3% (95% CI 13.9% to 25.3%) with chemotherapy alone. Among the 33 patients who completed 2 years of camrelizumab, 5-year OS rate was 84.3% (95% CI 66.4% to 93.2%), and 5-year duration of response rate was 46.5% (95% CI 24.9% to 65.6%) in the 32 responders. No new safety signals were noted. Conclusions: Camrelizumab plus carboplatin and pemetrexed as first-line therapy continued to demonstrate long-term OS benefit over carboplatin and pemetrexed, with manageable toxicity. Patients who completed 2 years of camrelizumab had enduring response and impressive OS. Current 5-year updated analysis further supports camrelizumab plus carboplatin and pemetrexed as a standard-of-care for previously untreated advanced non-squamous NSCLC without EGFR/ALK alterations. Trial registration number: NCT03134872.

15 May 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HLHeshu Liu
Heshu Liu
TWTao Wen
Tao Wen
YZYing Zhou
Ying Zhou
XFXiaona Fan
Xiaona Fan
TDTan Du
Tan Du
GAGuangyu An
Guangyu An
Background. Doublecortin-like kinase 1 (DCLK1) has been universally identified as a cancer stem cell (CSC) marker and is found to be overexpressed in many types of cancers including breast cancer. However, there is little data regarding the functional role of DCLK1 in breast cancer metastasis. In the present study, we sought to investigate whether and how DCLK1 plays a metastatic-promoting role in human breast cancer cells.Methods. We used Crispr/Cas9 technology to knock out DCLK1 in breast cancer cell line BT474, which basically possesses DCLK1 at a higher level, and stably overexpressed DCLK1 in another breast cancer cell line, T47D, that basically expresses DCLK1 at a lower level. We further analyzed the alterations of metastatic characteristics and the underlying mechanisms in these cells.Results. It was shown that, compared with the corresponding control cells, DCLK1 overexpression led to an increase in metastatic behaviors including enhanced migration and invasion of T47D cells. By contrast, forced depletion of DCLK1 drastically inhibited these metastatic characteristics in BT474 cells. Mechanistically, the epithelial-mesenchymal transition (EMT) program, which is critical for cancer metastasis, was prominently activated in DCLK1-overexpressing cancer cells, evidenced by a decrease in an epithelial marker ZO-1 and an enhancement in several mesenchymal markers including ZEB1 and Vimentin. In addition, DCLK1 overexpression induced the ERK MAPK pathway, which resultantly enhanced the expression of MT1-MMP that is also involved in cancer metastasis. Knockout of DCLK1 could reverse these events, further supporting a metastatic-promoting role for DCLK1.Conclusions. Collectively, our data suggested that DCLK1 overexpression may be responsible for the increased metastatic features in breast cancer cells. Targeting DCLK1 may become a therapeutic option for breast cancer metastasis.

1 January 2020 in Life Sciences
Verified
Journal Article
Closed access
RYRui Yan
Rui Yan
JLJianJian Li
JianJian Li
YZYing Zhou
Ying Zhou
LYLi Yao
Li Yao
RSRuya Sun
Ruya Sun
GAGuangyu An
Guangyu An

1 November 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
MLManyu Li
Manyu Li
CZChaofan Zeng
Chaofan Zeng
JYJiannan Yao
Jiannan Yao
YGYang Ge
Yang Ge
GAGuangyu An
Guangyu An

5 January 2022 in Translational Oncology
Verified
Journal Article
Open access
YGYang Ge
Yang Ge
HLHeshu Liu
Heshu Liu
YZYuanyuan Zhang
Yuanyuan Zhang
JLJian Liu
Jian Liu
RYRui Yan
Rui Yan
GAGuangyu An
Guangyu An
• Both DCLK1 long (DCLK1-iso1) and short (DCLK1-iso4) isoforms promote epithelial-mesenchymal transition in pancreatic cancer cells. • Immunosuppressive components are highly enriched in “mesenchymal” pancreatic cancer. • The infiltration of CD4 and CD8+ T cells decrease while the M2 macrophages increase in DCLK1-overexpressing tumors. • DCLK1 inhibitor could reverse EMT program and restore T-cells activity.

30 August 2021 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
SFshanshan fan
shanshan fan
YGYang Ge
Yang Ge
JLJian Liu
Jian Liu
HLHeshu Liu
Heshu Liu
RYRui Yan
Rui Yan
GAGuangyu An
Guangyu An
Background: Intrahepatic cholangiocarcinoma (ICC) is a malignant carcinoma with high rate of mortality. The current treatment is ineffective with poor survival time. Therefore, there is an urgent need for effective therapeutic drug regimens. The multi‐target tyrosine kinase inhibitor (TKI) anlotinib has been approved for treating non‐small cell lung cancer (NSCLC); however, the combined therapeutic regimen of anlotinib for ICC has not been investigated yet. This study aims to investigate the inhibitory effect of anlotinib and the mechanism of gemcitabine combination for ICC treatment.Methods: Two ICC cell lines, HCCC‐9810 and RBE cells, were used in this study. Cell Counting Kit‐8 (CCK‐8) was used to study the cell viability, and flow cytometry (FCM) was used to evaluate the apoptosis and cell cycle arrest. Compusyn software was used to calculate the combination index (CI) of anlotinib and gemcitabine. The protein expression rate of cleaved PARP/PARP and cleaved caspase‐3/caspase‐3 was detected by Western blotting.Results: Our result showed that the anlotinib and gemcitabine combination significantly inhibits the growth of ICC cell lines. Compusyn software results showed that the combination regimen had an anti‐tumor synergistic effect. FCM results showed that it promoted apoptosis. Moreover, it increased the protein expression rate of cleaved PARP/PARP and cleaved caspase‐3/caspase‐3. Finally, we found a synergistic anti‐tumor effect by increasing G0/G1 cell cycle arrest.Conclusion: The combination of anlotinib and gemcitabine can increase the anti‐tumor effect and may be a potential therapeutic drug regimen in a clinical setting.